surmount-1 trial tirzepatide non-diabetic obesity weight loss SURMOUNT-1: Adults achieve of 16% or more at 72 weeks with surmount-1 tirzepatide weight loss non-diabetic

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect

BPC-157 (Body Protection Compound-157) has no completed Phase II or Phase III human clinical trial data

( j ) Baseline dark and light phase activity levels

Preclinical studies combining BPC-157 with growth hormone demonstrated enhanced healing compared to either agent alone, consistent with BPC-157's mechanism of upregulating growth hormone receptor expression

Eli Lilly cannot submit the NDA until enough Phase 3 data is available to demonstrate both efficacy and safety across the intended patient populations